PRX 002

Drug Profile

PRX 002

Alternative Names: NEOD-002; PRX-002; PRX002/RG7935; RG 7935; RO 7046015

Latest Information Update: 16 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neotope Biosciences
  • Developer Roche
  • Class Monoclonal antibodies
  • Mechanism of Action Alpha-synuclein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 16 Jun 2017 Phase-II clinical trials in Parkinson's disease (Early-stage disease) in USA (IV) (NCT03100149)
  • 02 Apr 2017 Roche and Prothena Biosciences plan the PASADENA phase II trial for Parkinson's disease in USA (NCT03100149)
  • 24 Feb 2017 Prothena has patent protection for PRX 002 (Prothena's form 10-K, filed in February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top